Randomized Phase II Study of Pembrolizumab 200mg every12 Weeks Versus Every 3 Weeks in NSCLC With Clinical Benefit to Pembrolizumab Monotherapy: Multicenter International Study
Latest Information Update: 21 Mar 2025
At a glance
- Drugs Pembrolizumab (Primary)
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
Most Recent Events
- 18 Mar 2025 Planned End Date changed from 14 Mar 2025 to 14 Mar 2026.
- 25 Feb 2025 Planned End Date changed from 5 Jan 2025 to 14 Mar 2025.
- 02 Aug 2023 Planned End Date changed from 3 Nov 2023 to 5 Jan 2025.